Bandingkan Harga & Kinerja Medco Energi Internasional Tbk. (MEDC) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Medco Energi Internasional Tbk. dan Organon Pharma Indonesia Tbk.: Medco Energi Internasional Tbk. diperdagangkan di Rp1.555 (kapitalisasi pasar 39,46 T, volume 24 jam 55,01 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Medco Energi Internasional Tbk. jauh lebih besar — sekitar 378× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| MEDC | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 39,46 T | 104,4 M |
Volume | 55,01 jt | — |
Lot | 550,06 rb | — |
Perputaran | 87,49 M | — |
Harga Rata-rata | 1.590,64 | — |
Nilai Transaksi | 87,49 M | — |
Harga Ekuilibrium Indikatif | 1.555 | — |
Volume Ekuilibrium Indikatif | 13,38 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Medco Energi Internasional Tbk.
PT Medco Energi Internasional Tbk (the Company) was established within the framework of the Domestic Capital Investment Law No. 6 year 1968 as amended by Law No. 12 year 1970, based on notarial deed No. 19 of Imas Fatimah, S.H., dated June 9, 1980. Medco Energi Corporation is holding company for energy related business within the Medco Group of companies. On March 1997 the company cooperated with Myanmar Oil and Gas Enterprise plan to handle 8,000 m2 of suspended field in Myanmar. Company is a PMDN
Selengkapnya di halaman MEDC →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
